국소진행성 직장암에서 Irinotecan을 이용한 술전보강화학방사선치료 시 UGT1A1 유전자 다형태의 유용성 = The Efficacy of UGT1A1 Polymorphism in Chemoradiation Therapy Using Irinotecan in Patients with Locally Advanced Rectal Cancer

다국어 초록 (Multilingual Abstract)

Purpose: Irinotecan (CPT-11) is hydrolyzed to an active SN-38, which is further detoxicated to SN-38G through conjugation by uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) enzymes. There are many reports that UGT1A1 polymorphisms are associated with irinotecan related dose-limiting toxicity. The aim of the present study is to determine whether UGT1A1 polymorphisms affect individual variations of the toxicity due to and the tumor response to irinotecan via the alteration of bioavailability of SN-38 in Korean patients with locally advanced rectal cancer. Methods: Twenty patients with locally advanced rectal cancer, who had received surgery after irinotecan- containing chemoradiation from 2003 to 2006, were enrolled. We analyzed the association of UGT1A1 genotypes with toxicity and tumor response to chemoradiation therapy. A tumor response was assumed when a tumor regression grade I or II was obtained. Toxicity was graded in accordance with the NCI common toxicity criteria. Results: The frequence of -53(TA)6＞7 (UGT1A1*28), 211G＞A (UGT1A1*6), 686C＞A (UGT1A1*27), -3279T＞G (UGT1A1*60), and -3156G＞A were 25% (5/20), 25% (5/20), 0% (0/20), 55% (11/20), and 20% (4/20), respectively. There were five grade III neutropenia and one severe diarrhea. Patients with UGT1A1*28 and -3156G＞A showed higher complete tumor response rates (40% vs. 6.7%, P=0.07; 50% vs. 6.3%, P=0.08), but there was no differences in toxicity and tumor response between responders and non-responders. Patients with -3279T＞G (UGT1A1*60) showed a tendency for lower tumor response in tumor responders, but there was no statistically significant difference (P=0.07). Conclusions: This study suggested that -3279T＞G (UGT1A1*60) may be useful in predicting tumor response of irinotecan. In the future, further study is warranted using large numbers of cases to reach statistical significance.

참고문헌 (Reference)

1 Ritter JK, "and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini" phe (phe): 3257-61,

2 "UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity" 2 : 43-47, 2002

3 "UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan" 9 : 845-847, 1998

4 "Tobacco carcinogen-detoxifying enzyme UGT1A7 and its association with orolaryngeal cancer risk" 93 : 1411-1418, 2001

5 "The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): hematologic and evolutionary implications" 31 : 98-101, 2003

6 Rougier P, "Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer" 352 : 1407-1412, 1998

7 "Polymorphisms of the human UDP-glucuronosyltransferase (UGT) 1A7 gene in colorectal cancer" 50 : 851-856, 2002

8 "Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis" 60 : 6921-6926, 2000

9 Fuchs CS, "Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer" 21 : 807-814, 2003

10 Gupta E, "Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients" 15 : 1502-1510, 1997

11 Cancer 1994, "Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma" 2680-6,

12 Gupta E, "Metabolic fate of irinotecan in humans correlation of glucuronidation with diarrhea" 3723-5,

13 Saltz LB, "Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer" Irinotecan Study Group 343 : 905-914, 2000

14 "Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38" 44 : 854-860, 2004

15 "Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes" 15 : 295-301, 2005

16 Owens IS, "Gene structure at the human UGT1 locus creates diversity in isozyme structure, substrate specificity, and regulation" 51 : 305-338, 1995

17 "Contribution of two missense mutations (G71R and Y486D) of the bilirubin UDP glycosyltransferase (UGT1A1) gene to phenotypes of Gilbert's syndrome and Crigler-Najjar syndrome type II" 1406 : 267-273, 1998

18 "Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin" 24 : 2237-2244, 2006